Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Collecting data on maintaining anti-retroviral activity (quantitative HIV RNA determination)
and immunological activity (CD4 cells) after switching from protease inhibitor or NNRTI to
Nevirapine (Viramune®) and collecting of routinely observed laboratory data on lipids, and
liver enzymes.